I’ve thought for quite some time the Survaxm 2b trial would fail; however, I believe the Survaxm 2b control arm is possibly now/already being used as a patient level data external control arm for DCVax-L’s trial.
Ex has been all over the map on Survaxm 2b’s trial chances. Now he is wising up about that. It almost certainly failed.
He also finally concedes it’s control arm would likely provide a better patient level control arm match for DCVax-L’s phase iii.
He also acknowledges it’s possible Roswell shared their 2b data with NWBO.
He’ll hopefully be logically forced to concede one more thing soon.
Market Data 
Markets 
AI
